CochLear Total Long Term Liabilities 2023-2024 | CHEOY
CochLear total long term liabilities from 2023 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
- CochLear total long term liabilities for the quarter ending December 31, 2024 were $0.047B, a 0% increase year-over-year.
- CochLear total long term liabilities for 2024 were $0.179B, a 9.98% increase from 2023.
- CochLear total long term liabilities for 2023 were $0.163B, a 10.86% decline from 2022.
- CochLear total long term liabilities for 2022 were $0.183B, a 0% decline from 2021.
| CochLear Annual Total Long Term Liabilities (Millions of US $) |
|
|---|---|
| 2024 | $179 |
| 2023 | $163 |
| 2022 | $183 |
| 2021 | $0 |
| 2020 | $0 |
| 2019 | $0 |
| 2018 | $0 |
| 2017 | $0 |
| 2016 | $0 |
| CochLear Quarterly Total Long Term Liabilities (Millions of US $) |
|
|---|---|
| 2024-06-30 | $47 |
| 2023-12-31 | $42 |
| 2023-06-30 | $53 |
| 2022-06-30 | $56 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $13.493B | $1.488B |
| Cochlear Limited provides implantable hearing solutions principally in the Americas, Europe, the Middle East, Africa and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories and Baha bone conduction implants. Cochlear Limited is based in Sydney, Australia. | |||